TY - JOUR
T1 - New therapies for ovarian cancer
AU - Armstrong, Deborah K.
N1 - Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.
AB - In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.
UR - http://www.scopus.com/inward/record.url?scp=85048307608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048307608&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0034
DO - 10.6004/jnccn.2018.0034
M3 - Article
C2 - 29784743
AN - SCOPUS:85048307608
SN - 1540-1405
VL - 16
SP - 632
EP - 635
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 5S
ER -